Copyright Reports & Markets. All rights reserved.

Europe Oncology Anti-Cancer Drugs Market Report 2019

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Oncology Anti-Cancer Drugs Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Chemotherapy Market Performance (Volume)
      • 2.1.2 Targeted Therapy Market Performance (Volume)
      • 2.1.3 Immunotherapy (Biologic Therapy) Market Performance (Volume)
      • 2.1.4 Hormonal Therapy Market Performance (Volume)
      • 2.1.5 Others Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.2.1 Chemotherapy Market Performance (Value)
      • 2.2.2 Targeted Therapy Market Performance (Value)
      • 2.2.3 Immunotherapy (Biologic Therapy) Market Performance (Value)
      • 2.2.4 Hormonal Therapy Market Performance (Value)
      • 2.2.5 Others Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Blood Cancer (Leukaemia) Market Performance (Volume)
      • 3.1.2 Breast Cancer Market Performance (Volume)
      • 3.1.3 Gastrointestinal Cancer Market Performance (Volume)
      • 3.1.4 Respiratory/Lung Cancer Market Performance (Volume)
      • 3.1.5 Skin Cancer Market Performance (Volume)
      • 3.1.6 Other Cancers Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Amgen
      • 4.1.1 Amgen Profiles
      • 4.1.2 Amgen Product Information
      • 4.1.3 Amgen Oncology Anti-Cancer Drugs Business Performance
      • 4.1.4 Amgen Oncology Anti-Cancer Drugs Business Development and Market Status
    • 4.2 AstraZeneca
      • 4.2.1 AstraZeneca Profiles
      • 4.2.2 AstraZeneca Product Information
      • 4.2.3 AstraZeneca Oncology Anti-Cancer Drugs Business Performance
      • 4.2.4 AstraZeneca Oncology Anti-Cancer Drugs Business Development and Market Status
    • 4.3 Roche Diagnostics
      • 4.3.1 Roche Diagnostics Profiles
      • 4.3.2 Roche Diagnostics Product Information
      • 4.3.3 Roche Diagnostics Oncology Anti-Cancer Drugs Business Performance
      • 4.3.4 Roche Diagnostics Oncology Anti-Cancer Drugs Business Development and Market Status
    • 4.4 GlaxoSmithKline
      • 4.4.1 GlaxoSmithKline Profiles
      • 4.4.2 GlaxoSmithKline Product Information
      • 4.4.3 GlaxoSmithKline Oncology Anti-Cancer Drugs Business Performance
      • 4.4.4 GlaxoSmithKline Oncology Anti-Cancer Drugs Business Development and Market Status
    • 4.5 Merck
      • 4.5.1 Merck Profiles
      • 4.5.2 Merck Product Information
      • 4.5.3 Merck Oncology Anti-Cancer Drugs Business Performance
      • 4.5.4 Merck Oncology Anti-Cancer Drugs Business Development and Market Status
    • 4.6 Novartis
      • 4.6.1 Novartis Profiles
      • 4.6.2 Novartis Product Information
      • 4.6.3 Novartis Oncology Anti-Cancer Drugs Business Performance
      • 4.6.4 Novartis Oncology Anti-Cancer Drugs Business Development and Market Status
    • 4.7 AbbVie
      • 4.7.1 AbbVie Profiles
      • 4.7.2 AbbVie Product Information
      • 4.7.3 AbbVie Oncology Anti-Cancer Drugs Business Performance
      • 4.7.4 AbbVie Oncology Anti-Cancer Drugs Business Development and Market Status
    • 4.8 Sanofi
      • 4.8.1 Sanofi Profiles
      • 4.8.2 Sanofi Product Information
      • 4.8.3 Sanofi Oncology Anti-Cancer Drugs Business Performance
      • 4.8.4 Sanofi Oncology Anti-Cancer Drugs Business Development and Market Status
    • 4.9 EIMC United Pharmaceuticals
      • 4.9.1 EIMC United Pharmaceuticals Profiles
      • 4.9.2 EIMC United Pharmaceuticals Product Information
      • 4.9.3 EIMC United Pharmaceuticals Oncology Anti-Cancer Drugs Business Performance
      • 4.9.4 EIMC United Pharmaceuticals Oncology Anti-Cancer Drugs Business Development and Market Status
    • 4.10 Actavis
      • 4.10.1 Actavis Profiles
      • 4.10.2 Actavis Product Information
      • 4.10.3 Actavis Oncology Anti-Cancer Drugs Business Performance
      • 4.10.4 Actavis Oncology Anti-Cancer Drugs Business Development and Market Status

    5 Market Performance for Manufacturers

    • 5.1 Europe Oncology Anti-Cancer Drugs Sales (K Units) and Market Share by Manufacturers 2014-2020
    • 5.2 Europe Oncology Anti-Cancer Drugs Revenue (M USD) and Market Share by Manufacturers 2014-2020
    • 5.3 Europe Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
    • 5.4 Europe Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Germany Market Performance for Manufacturers
      • 6.1.1 Germany Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.1.2 Germany Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.1.3 Germany Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.1.4 Germany Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.1.5 Market Concentration
    • 6.2 UK Market Performance for Manufacturers
      • 6.2.1 UK Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.2.2 UK Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.2.3 UK Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.2.4 UK Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.2.5 Market Concentration
    • 6.3 France Market Performance for Manufacturers
      • 6.3.1 France Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.3.2 France Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.3.3 France Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.3.4 France Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.3.5 Market Concentration
    • 6.4 Russia Market Performance for Manufacturers
      • 6.4.1 Russia Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.4.2 Russia Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.4.3 Russia Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.4.4 Russia Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.4.5 Market Concentration
    • 6.5 Benelux Market Performance for Manufacturers
      • 6.5.1 Benelux Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.5.2 Benelux Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.5.3 Benelux Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.5.4 Benelux Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.5.5 Market Concentration
    • 6.6 Italy Market Performance for Manufacturers
      • 6.6.1 Italy Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.6.2 Italy Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.6.3 Italy Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.6.4 Italy Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.6.5 Market Concentration
    • 6.7 Spain Market Performance for Manufacturers
      • 6.7.1 Spain Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.7.2 Spain Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.7.3 Spain Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.7.4 Spain Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.8.2 Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.8.3 Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
      • 6.8.4 Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
      • 6.8.5 Market Concentration

    7 Europe Oncology Anti-Cancer Drugs Market Performance (Sales Point)

    • 7.1 Europe Oncology Anti-Cancer Drugs Sales (K Units) and Market Share by Regions 2014-2020
    • 7.2 Europe Oncology Anti-Cancer Drugs Revenue (M USD) and Market Share by Regions 2014-2020
    • 7.3 Europe Oncology Anti-Cancer Drugs Price (USD/Unit) by Regions 2014-2020
    • 7.4 Europe Oncology Anti-Cancer Drugs Gross Margin by Regions 2014-2020

    8 Development Trend for Regions (Sales Point)

    • 8.1 Europe Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.2 Germany Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.3 UK Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.4 France Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.5 Russia Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.6 Benelux Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.7 Italy Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.8 Spain Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Blood Cancer (Leukaemia) Industry
    • 11.2 Breast Cancer Industry
    • 11.3 Gastrointestinal Cancer Industry
    • 11.4 Respiratory/Lung Cancer Industry
    • 11.5 Skin Cancer Industry
    • 11.6 Other Cancers Industry

    12 Market Forecast 2021-2026

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
      • 12.1.1 Europe Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
      • 12.1.2 Europe Oncology Anti-Cancer Drugs Sales (K Units) and Growth Rate 2021-2026
      • 12.1.3 Germany Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.4 UK Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.5 France Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.6 Russia Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.7 Benelux Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.8 Italy Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.9 Spain Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.2 Sales (K Units) and Revenue (M USD) Forecast by Types 2021-2026
      • 12.2.1 Overall Market Performance
      • 12.2.2 Chemotherapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.2.3 Targeted Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.2.4 Immunotherapy (Biologic Therapy) Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.2.5 Hormonal Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.2.6 Others Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.3 Sales Forecast by Application 2021-2026
      • 12.3.1 Overall Market Performance
      • 12.3.2 Blood Cancer (Leukaemia) Sales and and Growth Rate 2021-2026
      • 12.3.3 Breast Cancer Sales and and Growth Rate 2021-2026
      • 12.3.4 Gastrointestinal Cancer Sales and and Growth Rate 2021-2026
      • 12.3.5 Respiratory/Lung Cancer Sales and and Growth Rate 2021-2026
      • 12.3.6 Skin Cancer Sales and and Growth Rate 2021-2026
      • 12.3.7 Other Cancers Sales and and Growth Rate 2021-2026
    • 12.4 Price (USD/Unit) and Gross Profit Forecast
      • 12.4.1 Europe Oncology Anti-Cancer Drugs Price (USD/Unit) Trend 2021-2026
      • 12.4.2 Europe Oncology Anti-Cancer Drugs Gross Profit Trend 2021-2026

    13 Conclusion

    In this report, the Oncology Anti-Cancer Drugs market is expected to be valued at USD xxx billion by 2026, growing at a CAGR of xx% between 2020 and 2026. In this study, sales and sales value (million USD) of major players in Europe market will be included.
    Sales and revenue by type/application from 2014-2026.
    Industry chain, market trend, downstream and upstream information is also included.

    Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Oncology Anti-Cancer Drugs for these regions, from 2014 to 2026 (forecast), including
    Germany
    UK
    France
    Russia
    Benelux
    Italy
    Spain

    Europe Oncology Anti-Cancer Drugs market competition by top manufacturers/players, with Oncology Anti-Cancer Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Amgen
    AstraZeneca
    Roche Diagnostics
    GlaxoSmithKline
    Merck
    Novartis
    AbbVie
    Sanofi
    EIMC United Pharmaceuticals
    Actavis

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Chemotherapy
    Targeted Therapy
    Immunotherapy (Biologic Therapy)
    Hormonal Therapy
    Others

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Oncology Anti-Cancer Drugs for each application, including
    Blood Cancer (Leukaemia)
    Breast Cancer
    Gastrointestinal Cancer
    Respiratory/Lung Cancer
    Skin Cancer
    Other Cancers

    If you have any special requirements, please let us know and we will offer you the report as you want.
    Buy now